Patrick M Sweeney & Associates Inc. Sells 20,492 Shares of Pfizer Inc. $PFE

Posted by Brenda Bartman on May 13th, 2026

Patrick M Sweeney & Associates Inc. trimmed its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 15.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 116,318 shares of the biopharmaceutical company’s stock after selling 20,492 shares during the period. Pfizer comprises about 1.8% of Patrick M Sweeney & Associates Inc.’s holdings, making the stock its 10th biggest holding. Patrick M Sweeney & Associates Inc.’s holdings in Pfizer were worth $2,896,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of PFE. World Investment Advisors increased its position in shares of Pfizer by 11.2% in the fourth quarter. World Investment Advisors now owns 397,952 shares of the biopharmaceutical company’s stock worth $9,909,000 after acquiring an additional 40,239 shares in the last quarter. Glass Wealth Management Co LLC lifted its position in shares of Pfizer by 1.1% in the 4th quarter. Glass Wealth Management Co LLC now owns 89,481 shares of the biopharmaceutical company’s stock valued at $2,228,000 after acquiring an additional 989 shares in the last quarter. Fourth Dimension Wealth LLC lifted its position in shares of Pfizer by 20.2% in the 4th quarter. Fourth Dimension Wealth LLC now owns 3,535 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 593 shares in the last quarter. Money Concepts Capital Corp boosted its stake in Pfizer by 0.3% in the 4th quarter. Money Concepts Capital Corp now owns 248,933 shares of the biopharmaceutical company’s stock worth $6,198,000 after purchasing an additional 682 shares during the period. Finally, AGH Wealth Advisors LLC boosted its stake in Pfizer by 4.5% in the 4th quarter. AGH Wealth Advisors LLC now owns 9,400 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 409 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 0.3%

Shares of NYSE:PFE opened at $25.88 on Wednesday. The firm has a fifty day moving average of $27.05 and a two-hundred day moving average of $26.18. The firm has a market capitalization of $147.51 billion, a P/E ratio of 19.76 and a beta of 0.35. Pfizer Inc. has a 12-month low of $21.97 and a 12-month high of $28.75. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio is currently 131.30%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Several articles argued that Pfizer looks “dirt cheap” and could be a long-term buy, reinforcing the view that the stock may have room to recover as investors focus on valuation and future growth potential. Article Title
Positive Sentiment: Pfizer and partner Arvinas reached a licensing transaction with Rigel Pharmaceuticals for the breast cancer drug VEPPANU (vepdegestrant), bringing in $85 million upfront and up to $320 million more in milestones plus royalties, which supports future cash flow and validates the asset. Article Title
Positive Sentiment: Additional coverage highlighted Pfizer’s earnings as stronger than the market expected, suggesting the company’s recent quarter may have been better than the stock’s muted reaction implied. Article Title
Neutral Sentiment: Commentary on Pfizer’s dividend raised questions about sustainability, but the discussion also noted the yield remains unusually high and could appeal to income-focused investors. Article Title
Neutral Sentiment: Analysts and market commentators continued to debate Pfizer’s long-term outlook, including whether oncology and next-generation therapies can offset the post-COVID revenue decline. Article Title
Negative Sentiment: Coverage also noted pressure on vaccine makers from softer U.S. demand and tougher policy conditions, a reminder that Pfizer’s vaccine-related businesses may face ongoing headwinds. Article Title

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent analyst reports. Morgan Stanley boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Guggenheim raised their target price on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Royal Bank Of Canada reissued an “underperform” rating and set a $25.00 price target on shares of Pfizer in a research report on Monday, April 20th. Barclays assumed coverage on Pfizer in a research note on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price objective for the company. Finally, Bank of America decreased their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $28.74.

View Our Latest Stock Report on PFE

Pfizer Profile

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.